Details of the Drug

General Information of Drug (ID: DMRI6YT)

Drug Name
BI 836880
Indication
Disease Entry ICD 11 Status REF
Neoplasm 2A00-2F9Z Phase 1 [1]
Wet age-related macular degeneration 9B78.3Z Phase 1 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
D62LKT
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Blocker [3]
Vascular endothelial growth factor (VEGF) TT9HKJA VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN Blocker [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Neoplasm
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiopoietin-2 (ANGPT2) DTT ANGPT2 3.47E-04 -0.31 -0.4
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03972150) A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03861234) A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Boehringer Ingelheim.